Ambrosia artemisiifolia pollen clinical trials
Also written MK-3641 and SCH 39641.
How each study uses ambrosia artemisiifolia pollen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 13 Mar 1924 · N/A · BLA 103880 (FDA, Purple Book)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2011 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses ambrosia artemisiifolia pollen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)CompletedPhase 3Merck Sharp & Dohme LLCNCT02478398Written as Short ragweed pollen allergen extract
- A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)CompletedPhase 3ALK-Abelló A/SNCT01469182Written as SCH 39641
- Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)CompletedPhase 2ALK-Abelló A/SNCT00978029Written as SCH 39641
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)CompletedPhase 2/3ALK-Abelló A/SNCT00770315Written as Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)CompletedPhase 2/3ALK-Abelló A/SNCT00783198Written as SCH 39641 6 Amb a 1-U
Given beside what is tested · 1 — ambrosia artemisiifolia pollen is usual care or a partner of the new treatment
Codes
What other systems call ambrosia artemisiifolia pollen · ClinicalTrials.gg INT016994
- UNII (FDA) K20Y81ACO3AMBROSIA ARTEMISIIFOLIA POLLENOne source FDA
- RxNorm 896135One source FDA
- NCI Thesaurus C85102Ambrosia artemisiifolia PollenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | K20Y81ACO3 | AMBROSIA ARTEMISIIFOLIA POLLEN | One source FDA |
| RxNorm | 896135 | — | One source FDA |
| NCI Thesaurus | C85102 | Ambrosia artemisiifolia Pollen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.